Medical/Pharmaceuticals
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of d...
2025-07-09 20:00
3367
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of...
2025-07-09 11:14
1946
LakeShore Biopharma Announces US$15 Million Private Placement Financing
BEIJING, July 8, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today ...
2025-07-08 19:25
1734
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently provided updates to investors on the st...
2025-07-08 10:41
3404
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
* STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] * STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially availa...
2025-07-08 10:08
1930
WuXi AppTec Receives MSCI ESG AAA Leader Rating
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating – the highest level – from MSCI in its lates...
2025-07-07 20:08
1737
Coreline Soft and Temple Health to Co-Host Webinar on AI-Driven Lung Cancer Screening and Improving Patient Outcomes
* Real-world outcomes: How AI improved both diagnostic efficiency, early
detection, and comorbidity detection
* Deep dive into the precision technology of the FDA-cleared platform, AVIEW
LCS Plus PHILADELPHIA and SEOUL, South Korea, July 7, 2025 /PRNewswire/ --
Coreline Soft
2025-07-07 20:00
1741
The Voices of Persons Affected by Hansen's Disease Move the World: 3rd Global Forum Held in Bali, Indonesia
TOKYO, July 7, 2025 /PRNewswire/ -- In a landmark gathering that placed lived experience at the center of global health discourse, the 3rd Global Forum of People's Organizations on Hansen's Disease was held inBali, Indonesia, from July 4 to 6, 2025. Organized by the Sasakawa Leprosy (Hansen's Dis...
2025-07-07 19:00
1429
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor
2025-07-07 13:00
1429
ESG | HitGen Releases Its Inaugural Sustainability Report
CHENGDU, China, July 4, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced the release of its inaugural sustainability report, aiming to present the company's philosophies and policies in environmental, social, and governance ("ESG")...
2025-07-04 19:00
3794
NECC Selects MedMinder to Transform Their Medication Management for Individuals with Autism They Serve
NORWOOD, Mass., July 3, 2025 /PRNewswire/ -- The New England Center for Children (NECC), a globally recognized leader in autism education and research, has contracted with MedMinder, to enhance the safety, consistency, and reliability of medication management across its programs. The collaborati...
2025-07-04 01:52
1953
Fangzhou Tops China's App Store Chart for Healthcare Apps
GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in theJune 2025 China AppStore Healthcare TOP100 Free APP Rankings with its Fangzhou Online Pharmacy App, according to a report by ...
2025-07-03 18:43
2087
MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform
BOSTON, July 3, 2025 /PRNewswire/ -- MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment ofMaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer. The move comes as MOTE accelerates development of its MOBILIZ...
2025-07-03 18:07
2048
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispec...
2025-07-03 14:46
2144
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
* ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins * Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically significant and clinically meaningfulbenefits to patien...
2025-07-03 08:08
2123
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement * Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing da...
2025-07-03 07:09
2019
Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
- First participants with obesity or overweight with at least one weight-r elatedcomorbidity have been dosed in a U.S. 13-week Phase IIa study of small m oleculeoral GLP-1 receptor agonist ASC30. - ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction f...
2025-07-03 07:00
2104
SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response
SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately assess and predict therapeutic outcomes in lymphoma patients across different subtypes—potentially transforming how clinic...
2025-07-02 23:00
1984
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions. In conjunction with their recent acquisition of V...
2025-07-02 21:00
2212
[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria
* Gram-negative bacterial infections are becoming an increasingly serious global health issue * U.S. patent applications filed for three novel drug candidates: PKL200, TSL2200, and EAL2200 * Continued diversification of business initiatives to address Gram-negative bacterial threats BOSTON ...
2025-07-02 20:00
1870
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 286 media titles]
2025-12-10 16:00
